IGC Pharma, Inc. (IGC)
2025-06-30 | 2024-12-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 328 | 257 | 412 | 272 |
| Research and development expenses | 851 | 852 | 917 | 889 |
| Cost of revenue | 174 | 153 | 214 | 109 |
| Selling, general, and administrative expenses | 1,208 | 1,130 | 1,041 | 1,670 |
| Operating loss | -1,905 | -1,878 | -1,760 | -2,396 |
| Other income, net | 306 | 49 | 43 | 18 |
| Loss before income taxes | -1,599 | -1,829 | -1,717 | -2,378 |
| Income tax expense/benefit | - | - | - | - |
| Net loss attributable to common stockholders | -1,599 | -1,829 | -1,717 | -2,378 |
| Foreign currency translation adjustments | -3 | -18 | -15 | -3 |
| Comprehensive loss | -1,602 | -1,847 | -1,732 | -2,381 |
| Basic & diluted eps | - | - | - | -0.03 |
| Basic eps | - | - | - | - |
| Basic eps | - | - | - | 11,000,000 |
| Basic eps | - | - | - | 0.61 |
| Basic and diluted (in dollars per share) | -0.02 | -0.02 | -0.02 | - |
| Basic and diluted (in dollars per share) | -0.02 | -0.02 | -0.02 | - |
| Weighted-average number of shares used in computing loss per share amounts (in shares) | 83,027,117 | 77,633,004 | 76,007,129 | 72,813,538 |
| Weighted-average number of shares used in computing loss per share amounts (in shares) | 83,027,117 | 77,633,004 | 76,007,129 | - |